



International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE THE NEUROENDOCRINOLOGY OF CHRONIC STRESS:
EVALUATING THE CLINICAL EFFICACY OF ASHWAGANDHA
(WITHANIA SOMNIFERA) ON SERUM CORTISOL AND
PSYCHOSOCIAL WELL-BEING

DOI [https://doi.org/10.31435/ijitss.1\(49\).2026.4904](https://doi.org/10.31435/ijitss.1(49).2026.4904)

RECEIVED 15 December 2025

ACCEPTED 04 February 2026

PUBLISHED 18 February 2026

LICENSE



The article is licensed under a **Creative Commons Attribution 4.0 International License**.

© The author(s) 2026.

This article is published as open access under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

THE NEUROENDOCRINOLOGY OF CHRONIC STRESS: EVALUATING THE CLINICAL EFFICACY OF ASHWAGANDHA (WITHANIA SOMNIFERA) ON SERUM CORTISOL AND PSYCHOSOCIAL WELL-BEING

Julia Weronika Mieszkowska (Corresponding Author, Email: juliajard4@gmail.com)
Healthcare Centre in Łęczycza, Zachodnia 6, 99-100 Łęczycza, Poland
ORCID ID: 0009-0001-7699-9880

Norbert Grabias
Karol Jonscher Municipal Medical Center, Łódź, Poland
ORCID ID: 0009-0009-3681-5096

Jędrzej Piotrowski
Copernicus Memorial Hospital, Łódź, Poland
ORCID ID: 0000-0001-8044-5496

Paulina Jarząbek
Medical University of Łódź, Łódź, Poland
ORCID ID: 0009-0003-9859-1362

Maria Rajkowska
Copernicus Memorial Hospital, Łódź, Poland
ORCID ID: 0009-0005-2822-0595

Aleksandra Włodarczyk
Copernicus Memorial Hospital, Łódź, Poland
ORCID ID: 0009-0007-5456-6703

Radosław Gryko
Copernicus Memorial Hospital, Łódź, Poland
ORCID ID: 0009-0002-8215-7011

Bernard Myszewski
Copernicus Memorial Hospital, Łódź, Poland
ORCID ID: 0009-0000-0027-0789

Anna Kinga Tejchma
University Clinical Hospital No. 2 of the Medical University of Łódź, Łódź, Poland
ORCID ID: 0009-0007-7322-5517

Łukasz Dominik Woźniak
Medical University of Łódź, Łódź, Poland
ORCID ID: 0009-0007-5634-3810

ABSTRACT

Background: Chronic stress is a pervasive global health challenge characterized by the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. This neuroendocrine imbalance leads to elevated serum cortisol, which subsequently triggers systemic disruptions in reproductive health, metabolic homeostasis, and psychosocial well-being. *Withania somnifera* (Ashwagandha), a premier adaptogen, is increasingly recognized for its ability to modulate these multifaceted stress responses.

Objective: This review evaluates the clinical efficacy of Ashwagandha in reducing serum cortisol and enhancing well-being, while synthesizing its systemic impact on the reproductive, metabolic, immune, and sleep systems.

Methods: A comprehensive synthesis of over 48 contemporary sources, including randomized controlled trials (RCTs) and meta-analyses, was conducted to assess hormonal, psychometric, and physiological outcomes.

Results: Evidence consistently demonstrates that standardized Ashwagandha extracts (240–600 mg/daily) reduce serum cortisol levels by 11% to 32%. These changes correlate with significant improvements in anxiety (PSS-10, HAM-A) and sleep parameters, specifically reduced sleep onset latency and enhanced efficiency. Beyond the HPA axis, Ashwagandha restores the hypothalamic-pituitary-gonadal (HPG) axis, significantly improving sperm concentration and testosterone levels in males. Metabolic benefits include modest weight reduction and improved insulin sensitivity, while ergogenic effects manifest as increased VO₂max and accelerated muscular recovery. Furthermore, the herb exhibits immunomodulatory properties and subtle influences on thyroid indices (HPT axis), alongside emerging geroprotective potential. While generally safe, clinical monitoring for thyroid dysfunction is advised.

Conclusion: Ashwagandha functions as a robust multi-systemic regulator. Its ability to restore homeostatic balance across the HPA, HPG, and HPT axes justifies its integration into evidence-based protocols for stress management, metabolic health, and physical vitality.

KEYWORDS

Withania Somnifera, HPA Axis, Cortisol, Psychosocial Well-Being, Chronic Stress, Ashwagandha

CITATION

Julia Weronika Mieszkowska, Norbert Grabias, Jędrzej Piotrowski, Paulina Jarząbek, Maria Rajkowska, Aleksandra Włodarczyk, Radosław Gryko, Bernard Myszewski, Anna Kinga Tejchma, Łukasz Dominik Woźniak. (2026) The Neuroendocrinology of Chronic Stress: Evaluating the Clinical Efficacy of Ashwagandha (*Withania somnifera*) on Serum Cortisol and Psychosocial Well-Being. *International Journal of Innovative Technologies in Social Science*. 1(49). doi: 10.31435/ijitss.1(49).2026.4904

COPYRIGHT

© The author(s) 2026. This article is published as open access under the **Creative Commons Attribution 4.0 International License (CC BY 4.0)**, allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

1. Introduction

Chronic stress has evolved into a pervasive systemic challenge in modern society, transcending individual psychological distress to become a significant driver of global morbidity. In contemporary clinical research, chronic stress is characterized as a state of prolonged physiological "hyperarousal" that disrupts homeostatic equilibrium and impairs psychosocial well-being (Basta et al., 2007; Levenson et al., 2015). This state is fundamentally mediated by the dysregulation of the neuroendocrine system, specifically the hypothalamic-pituitary-adrenal (HPA) axis, which governs the body's response to sustained environmental and psychosocial demands (Herman et al., 2016; Patriquin & Mathew, 2017).

The neurobiology of the stress response involves an integrated cascade where the release of corticotropin-releasing hormone (CRH) stimulates the secretion of adrenocorticotrophic hormone (ACTH), ultimately triggering the adrenal cortex to produce glucocorticoids, primarily cortisol (Herman et al., 2016). While acute cortisol elevation is adaptive, chronic hypercortisolemia leads to "allostatic load," resulting in systemic inflammation, metabolic dysfunction, and neuroanatomical changes (Sinha, 2008; Yaribeygi et al., 2017). Critically, the impact of HPA axis dysregulation extends beyond the nervous system, triggering secondary disruptions in other vital endocrine pathways, including the hypothalamic-pituitary-thyroid (HPT) and hypothalamic-pituitary-gonadal (HPG) axes (Ambiye et al., 2013; Gannon et al., 2014).

Withania somnifera (L.) Dunal, commonly known as Ashwagandha, is a cornerstone of Ayurvedic medicine and a rigorously studied adaptogen. Bioactive steroidal lactones, particularly withanolides, are

believed to provide a stabilizing effect on the neuroendocrine system by attenuating HPA axis "hyperdrive" (Mikulska et al., 2023; Paul et al., 2021). Clinical evidence demonstrates that standardized Ashwagandha extracts significantly reduce serum cortisol levels and improve psychometric scores for anxiety and stress (Chandrasekhar et al., 2012; Lopresti et al., 2019a).

Beyond its primary anxiolytic effects, the therapeutic reach of Ashwagandha encompasses a broad spectrum of physiological systems often compromised by chronic stress. Emerging research highlights its potential to restore male reproductive health by enhancing sperm concentration and testosterone levels through HPA-HPG axis crosstalk (Ambiye et al., 2013; Sengupta et al., 2018). Furthermore, its role in metabolic regulation -specifically regarding weight management and insulin sensitivity-offers a promising avenue for mitigating stress-induced metabolic syndrome (Choudhary et al., 2017; Samadi Noshahr et al., 2015). The herb also demonstrates ergogenic properties, improving cardiorespiratory endurance (VO₂max) and muscular recovery, as well as immunomodulatory effects that may boost innate and adaptive immunity (Bonilla et al., 2021; Tharakan et al., 2021; Verma et al., 2024). Finally, its documented impact on sleep architecture and its potential as a geroprotector suggest a multifaceted role in promoting long-term physiological resilience and healthspan (Cheah et al., 2021; Vittal & Vinciguerra, 2025).

Despite the growing body of literature, a comprehensive evaluation focusing on the convergence of neuroendocrine markers and these diverse systemic outcomes is essential to validate Ashwagandha's role in modern medicine. The objective of this review is to evaluate the clinical efficacy of *Withania somnifera* in modulating serum cortisol and enhancing well-being, while critically assessing its multifaceted impacts on reproductive, metabolic, and physical health.

2. Methodology

The present review was conducted through a systematic synthesis of contemporary scientific literature to evaluate the clinical efficacy of *Withania somnifera* on neuroendocrine stress markers and psychosocial well-being. The methodology was designed to ensure a high level of evidence by prioritizing human clinical trials and comprehensive analytical reviews.

2.1. Search Strategy and Data Sources

A systematic search was performed across major electronic databases, including PubMed/MEDLINE, Embase, Scopus, Google Scholar, and the Cochrane Central Register of Controlled Trials (CENTRAL). To ensure both scientific depth and clinical relevance, the search included foundational phytochemical and pharmacological studies dating back to 2000, which established the chemical profile of the plant. However, the evaluation of clinical efficacy, safety, and modern standardization (e.g., KSM-66, Shoden) was strictly focused on randomized controlled trials and meta-analyses published between 2009 and 2025.

The following keywords and Boolean operators were utilized to identify relevant publications:

- ("Withania somnifera" OR "Ashwagandha") AND ("cortisol" OR "hydrocortisone")
- ("Ashwagandha") AND ("stress" OR "anxiety" OR "psychosocial well-being")
- ("Withania somnifera") AND ("HPA axis" OR "hypothalamic-pituitary-adrenal axis")
- ("Ashwagandha") AND ("thyroid" OR "testosterone" OR "metabolic health")

2.2. Inclusion and Exclusion Criteria

To maintain objective rigor, specific criteria were established for the selection of the 48 sources analyzed in this review:

• **Inclusion Criteria:** (1) Randomized, double-blind, placebo-controlled trials (RCTs) involving human subjects; (2) Systematic reviews and meta-analyses; (3) Peer-reviewed observational studies and case reports regarding safety and specific endocrine interactions; (4) Articles published in the English language.

• **Exclusion Criteria:** (1) Studies with insufficient statistical power or ambiguous methodologies; (2) Non-peer-reviewed content (e.g., conference abstracts or grey literature); (3) Studies focusing solely on non-standardized traditional formulations without quantified bioactive markers.

2.3. Data Extraction and Quality Assessment

Data were extracted from the selected sources with a focus on primary outcomes (serum cortisol levels) and secondary outcomes (scores on the Perceived Stress Scale [PSS-10], Hamilton Anxiety Rating Scale [HAM-A], sleep parameters, and metabolic indices). Each study was critically appraised for its methodology, dosage consistency, and the standardization of the *Withania somnifera* extract used. The synthesis prioritized meta-analyses of RCTs as the gold standard for clinical evidence.

3. Neuroendocrinology of the Stress Response: Pathophysiology

To understand the therapeutic potential of *Withania somnifera*, it is first necessary to delineate the neuroendocrine architecture of the stress response that the herb purports to modulate. The stress response is a highly conserved biological mechanism designed to maintain homeostasis in the face of physiological or psychological threats.

3.1. Physiology of the HPA Axis: From PVN to Adrenal Cortex

The central regulator of this response is the hypothalamic-pituitary-adrenal (HPA) axis. As described by Herman et al. (2016), the activation of the HPA axis is initiated in the paraventricular nucleus (PVN) of the hypothalamus. Upon exposure to a stressor, parvocellular neurosecretory neurons in the PVN release corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) into the hypophyseal portal circulation. These neuropeptides stimulate the anterior pituitary gland to synthesize and secrete adrenocorticotrophic hormone (ACTH). ACTH subsequently acts on the zona fasciculata of the adrenal cortex, triggering the synthesis and release of glucocorticoids, primarily cortisol in humans (Herman et al., 2016; Speers et al., 2021).

3.2. Glucocorticoid Signaling and Negative Feedback Loops

Under physiological conditions, cortisol secretion is tightly regulated by negative feedback mechanisms. Circulating glucocorticoids bind to glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) in the hippocampus, hypothalamus, and pituitary gland, thereby inhibiting further release of CRH and ACTH. This termination of the stress response is critical for preventing the deleterious effects of prolonged glucocorticoid exposure (Herman et al., 2016). However, in chronic stress states, this feedback mechanism becomes dysregulated, leading to persistent hypercortisolemia or blunted HPA axis reactivity, both of which are hallmarks of stress-related pathologies (Yaribeygi et al., 2017).

3.3. The Concept of Allostatic Load and Cellular Stress

The prolonged activation of these neural and endocrine systems results in "allostatic load" -the cumulative wear and tear on the body. While acute stress is adaptive, mobilizing energy via gluconeogenesis and lipolysis, chronic stress shifts this adaptation into pathology. Speers et al. (2021) note that chronic exposure to elevated cortisol is associated with neurotoxic effects, particularly in the hippocampus. Furthermore, this allostatic load involves a transition from endocrine signaling to systemic oxidative stress. As highlighted by Yaribeygi et al. (2017), chronic hypercortisolemia accelerates the production of reactive oxygen species (ROS) and triggers the release of pro-inflammatory cytokines, such as TNF- α and IL-6. This state of low-grade systemic inflammation further sensitizes the HPA axis, creating a pathological cycle of "inflammaging" (Wiciński et al., 2024; Paul et al., 2021).

3.4. Impact on Neurotransmission

Beyond the endocrine cascade, chronic stress profoundly disrupts neurotransmitter systems, creating an imbalance between excitatory (glutamate) and inhibitory (GABA) transmission. The downregulation of GABAergic tone and the upregulation of glutamatergic activity contribute to the hyperexcitability of the amygdala, manifesting clinically as anxiety and insomnia (Speers et al., 2021). This neurochemical landscape provides a specific therapeutic target for adaptogens like *Withania somnifera*, which demonstrate GABA-mimetic activity, as discussed in subsequent sections.

3.5. Stress-Induced Impairment of Neuroplasticity and BDNF

Chronic HPA axis activation also impairs neuroplasticity by modulating the expression of neurotrophic factors. Research indicates that sustained psychological stress leads to a significant decline in Brain-Derived Neurotrophic Factor (BDNF) levels within the hippocampus and prefrontal cortex (Patriquin & Mathew, 2017; Yang et al., 2015). Glucocorticoid-induced suppression of BDNF inhibits neurogenesis and alters dendritic morphology, resulting in structural atrophy. This loss of synaptic plasticity correlates with the cognitive deficits and emotional dysregulation frequently observed in chronically stressed individuals (Yaribeygi et al., 2017).

3.6. Integration with the Sympathetic-Adreno-Medullary (SAM) Axis

Finally, the neuroendocrine stress response is characterized by the integrated action of the HPA and the Sympathetic-Adreno-Medullary (SAM) axes. While the HPA axis provides a sustained hormonal response, the SAM axis mediates the immediate "fight-or-flight" reaction through the release of catecholamines (epinephrine and norepinephrine). In chronic stress, persistent SAM activation leads to autonomic imbalance and cardiovascular strain (Yaribeygi et al., 2017). The interplay between these two axes defines the total physiological burden on the individual, highlighting the necessity for interventions that can restore equilibrium across multiple regulatory systems.

4. Phytochemistry and Pharmacological Mechanisms of *Withania somnifera*

To elucidate how *Withania somnifera* modulates the neuroendocrine parameters described previously, it is necessary to examine its phytochemical complexity and diverse molecular targets. The herb's pharmacological efficacy is not attributable to a single molecule but rather to a synergistic complex of bioactive compounds that exert pleiotropic effects on the central nervous system (CNS) and peripheral tissues.

4.1. Phytochemical Profile: Withanolides, Alkaloids, and Sitoindosides

The pharmacological architecture of *Withania somnifera* is defined primarily by withanolides -a group of over 40 naturally occurring C28-steroidal lactone triterpenoids built on an ergostane framework (Mirjalili et al., 2009). Among these, Withaferin A, Withanolide A, and Withanolide D are the most extensively characterized for their bioactivity. While withanolides are often concentrated in the leaves, standardized root extracts focus on these lipophilic compounds due to their ability to cross the blood-brain barrier and interact with neuronal signaling pathways (Paul et al., 2021). Beyond pure withanolides, the plant contains "sitoindosides" -glycosylated withanolides that enhance its adaptogenic potential -and various alkaloids such as somniferine and anahygrine, which contribute to its systemic effects (Singh et al., 2011; Wiciński et al., 2024).

4.2. Modulation of Neurotransmission and Neuroplasticity

A primary mechanism by which Ashwagandha attenuates stress and anxiety is through the modulation of the gamma-aminobutyric acid (GABA) system. Extracts exhibit GABA-mimetic properties, acting on mammalian ionotropic GABA-A and GABA-B receptors to induce neuronal hyperpolarization (Speers et al., 2021). This mechanism directly addresses the cortical hyperarousal that drives chronic insomnia and anxiety. Furthermore, innovation in the understanding of its sleep-promoting effects includes the identification of Triethylene glycol (TEG) and TEG-like fractions, which can exert significant stress-resistance effects independently of withanolide content (Dey et al., 2018). Ashwagandha also supports neuroplasticity by increasing the expression of Brain-Derived Neurotrophic Factor (BDNF) and inhibiting acetylcholinesterase (AChE) activity, thereby preserving cholinergic transmission in the hippocampus (Patriquin & Mathew, 2017; Er et al., 2025).

4.3. Neuroimmune Interface: Inhibition of NF-κB and Nrf2 Activation

Chronic stress triggers a transition to a pro-inflammatory state, characterized by elevated cytokines. Recent findings demonstrate that Ashwagandha reverses this trend by inhibiting the Nuclear Factor-kappa B (NF-κB) signaling pathway (Krishna Raju et al., 2023). This leads to a significant downregulation of pro-inflammatory markers, including Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1beta (IL-1beta), and Interleukin-6 (IL-6). Concurrently, the herb induces the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway, which serves as a master regulator of the body's internal antioxidant response (Jamnekar et al., 2025). By addressing the immune-endocrine interface, Ashwagandha prevents cytokine-induced disruption of the HPA axis.

4.4. Systemic Antioxidant Defense and Anti-apoptotic Activity

Psychological stress manifests as systemic oxidative stress, leading to lipid peroxidation and cellular damage. Ashwagandha acts as a potent scavenger of Reactive Oxygen Species (ROS) and enhances endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase (Sengupta et al., 2018; Shukla et al., 2011). This reduction in oxidative damage is intrinsically linked to its neuroprotective and anti-apoptotic properties. Preclinical models indicate that Ashwagandha modulates the expression of apoptotic proteins -specifically by decreasing the pro-apoptotic Bax and increasing the anti-apoptotic Bcl-2 -thereby protecting hippocampal neurons from corticosterone-induced atrophy (Gokdemir et al., 2025).

4.5. Mitochondrial Bioenergetics and ATP Preservation

A unique adaptogenic mechanism involves the optimization of cellular energy management. Chronic stress leads to a rapid depletion of Adenosine Triphosphate (ATP) and a decline in mitochondrial membrane potential. Standardized extracts of *Withania somnifera* have been shown to significantly inhibit this ATP depletion and increase the energy charge of the adenylate pool under stressful conditions (Bhattacharyya et al., 2009). This bioenergetic resilience helps explain the herb's clinical efficacy in reducing physical fatigue and enhancing VO_{2max} , positioning it as a comprehensive metabolic and physiological regulator.

5. Clinical Efficacy: Impact on Neuroendocrine Biomarkers and HPA Axis Regulation

The primary objective of this review is to evaluate whether the mechanistic potential of *Withania somnifera* translates into measurable neuroendocrine changes in humans. An analysis of randomized, double-blind, placebo-controlled trials (RCTs) confirms that the herb exerts a potent regulatory effect on the HPA axis, evidenced primarily by significant reductions in circulating glucocorticoids and improvements in physiological resilience.

5.1. Modulation of Serum and Salivary Cortisol Levels

Cortisol serves as the principal biomarker for HPA axis hyperactivity. The systematic review and meta-analysis by Della Porta et al. (2023), which synthesized data from multiple clinical trials, concluded that Ashwagandha supplementation consistently results in a statistically significant decrease in cortisol levels, with reductions ranging from 11 percent to 32 percent compared to placebo.

Specific RCTs provide granular data on this effect. In the landmark study by Chandrasekhar et al. (2012), individuals treated with 600 mg of high-concentration full-spectrum extract daily exhibited a 27.9 percent reduction in serum cortisol levels after 60 days. This was accompanied by a nearly 44 percent drop in scores on the Perceived Stress Scale (PSS-10). These findings are corroborated by Choudhary et al. (2017) and Salve et al. (2019), the latter of which reported a highly significant decrease in serum cortisol ($p < 0.0001$) in adults under chronic stress.

Furthermore, measurements of salivary cortisol -which reflect the biologically active "free" fraction of the hormone -showed a notable morning reduction of 23 percent in the treatment group in a study by Lopresti et al. (2019a). The most recent clinical data from Pandit et al. (2024) further solidify this evidence, demonstrating that standardized extracts significantly lower serum cortisol even in populations with exceptionally high baseline stress markers.

5.2. Restoration of the HPA Axis Balance and Physical Recovery

Chronic stress is often characterized by the "pregnenolone steal" or "cortisol steal" phenomenon, where hormonal precursors are diverted towards cortisol synthesis at the expense of anabolic hormones. *Withania somnifera* appears to reverse this catabolic state. Lopresti et al. (2019b) observed that alongside cortisol reduction, there was an 8% increase in Dehydroepiandrosterone-sulphate (DHEA-S), an adrenal androgen that antagonizes the neurotoxic effects of cortisol and supports emotional regulation.

This hormonal rebalancing translates into enhanced physical recovery and performance. A Bayesian meta-analysis by Bonilla et al. (2021) confirmed that Ashwagandha supplementation significantly improves physical performance and recovery variables. By optimizing the cortisol-to-testosterone ratio, the herb prevents stress-induced muscle catabolism and enhances oxygen consumption efficiency (VO_{2max}). These ergogenic benefits are further supported by studies on male reproductive health, where Ashwagandha was found to increase testosterone levels and improve semen quality by mitigating oxidative stress within the HPG axis (Ambiye et al., 2013; Sengupta et al., 2018).

5.3. Cognitive Enhancement and "Brain Fog" Mitigation

Beyond hormonal markers, recent trials have focused on the cognitive consequences of chronic stress, often referred to as "brain fog." Remenapp et al. (2022) conducted a randomized, double-blind, placebo-controlled study using a specific root and leaf extract (NooGandha) at doses of 225 mg and 400 mg. The researchers found that supplementation led to significant improvements in complex attention, executive function, and psychomotor speed compared to the placebo group. While a reduction in scores on the 'Food Cravings Questionnaire-Trait' was observed during the study, these changes did not reach statistical significance when compared directly to the placebo group, suggesting a possible time effect across all participants. Nevertheless, the enhancement of objective cognitive markers supports the role of Ashwagandha in preserving cognitive vitality under stress. This aligns with findings by Vittal and Vinciguerra (2025), who emphasize that Ashwagandha's neuroprotective effects contribute to preserving cognitive vitality in aging populations exposed to cumulative allostatic load.

5.4. Psychometric Outcomes: Anxiety and Sleep Quality

Biochemical changes correlate strongly with subjective improvements. In the study by Choudhary et al. (2017), the reduction in cortisol was accompanied by a 32.7 percent reduction in PSS scores and a marked decrease in emotional eating behaviors.

Regarding sleep disturbances, which are a hallmark of HPA axis dysregulation, a systematic review and meta-analysis by Cheah et al. (2021) confirmed that Ashwagandha extract offers a significant benefit in improving sleep efficiency and reducing sleep onset latency (SOL). Langade et al. (2019, 2021) provided definitive evidence that Ashwagandha administration leads to a significant reduction in the Hamilton Anxiety Rating Scale (HAM-A) and improves overall sleep architecture in both healthy individuals and those with clinical insomnia. These results demonstrate that Ashwagandha acts as a potent stabilizer of the circadian rhythm, which is often disrupted during chronic stress (Kelgane et al., 2020).

6. Safety Profile, Adverse Events, and Drug Interactions

While *Withania somnifera* is generally regarded as safe and is classified as "Generally Recognized as Safe" (GRAS) in many regulatory frameworks, its potent pharmacological activity implies specific contraindications and potential interactions that warrant clinical attention. Recent systematic reviews and case reports have clarified the safety boundaries of its usage, particularly concerning thyroid function, hepatic metabolism, and drug-drug interactions.

6.1. General Tolerability and Common Adverse Events

In the majority of randomized controlled trials (RCTs), *Withania somnifera* demonstrates a favorable safety profile. The systematic review by Marchi et al. (2025), which analyzed 14 studies involving over 700 participants, concluded that the herb is well-tolerated for the management of mental health symptoms.

However, mild adverse events are occasionally reported. Clinical data from Chandrasekhar et al. (2012) and Salve et al. (2019) indicate that a small percentage of participants may experience transient gastrointestinal symptoms, such as nausea, abdominal discomfort, or loose stools. These effects are generally self-limiting and do not necessitate discontinuation of therapy. Lopresti et al. (2019a) and Tharakan et al. (2021) further confirmed that hematological and biochemical parameters-including liver and kidney function tests-remain within normal limits after sustained supplementation, indicating a lack of systemic toxicity in healthy populations.

6.2. Thyroid Modulation: A Double-Edged Sword

One of the most clinically significant mechanisms of *Withania somnifera* is its stimulating effect on the Hypothalamic-Pituitary-Thyroid (HPT) axis. While this property is beneficial for patients with subclinical hypothyroidism, it presents a significant risk for euthyroid or hyperthyroid individuals.

Gannon et al. (2014) provided precise data on this phenomenon, showing that thyroxine (T4) levels increased in subjects receiving the extract, with elevations ranging from 7 percent to 24 percent. Notably, a case report by Hayashi et al. (2024) documented a rare instance of painless thyroiditis linked to Ashwagandha. The patient, a 47-year-old male, presented with classic symptoms of thyrotoxicosis -including fever, weight loss, and fatigue -which resolved only after the herb was discontinued. This case underscores the critical need for monitoring thyroid hormones (TSH, fT4) in patients, particularly those with a history of thyroid autoimmunity or those currently taking thyroid hormone replacement therapy.

6.3. Hepatic Safety and Idiosyncratic Reactions

Although most large-scale trials show no hepatotoxicity, rare and idiosyncratic cases of liver injury have been discussed in recent literature. Wiciński et al. (2024) reviewed emerging reports of Ashwagandha-induced liver injury (DILI). These reactions typically manifest as cholestatic jaundice and are currently classified as extremely rare.

The potential for hepatic interactions exists due to the herb's influence on the Cytochrome P450 enzyme system. While Tharakan et al. (2021) observed no biochemical changes in their cohort, clinicians are advised to monitor liver enzymes in patients with pre-existing hepatic conditions or those taking concurrent medications that are metabolized via similar pathways.

6.4. Clinically Relevant Drug Interactions

Based on its phytochemical properties and molecular targets, *Withania somnifera* may interact with several classes of pharmaceutical agents:

1. **Sedatives and Anxiolytics:** Due to its GABA-mimetic activity (Speers et al., 2021), Ashwagandha may potentiate the effects of benzodiazepines, barbiturates, or other CNS depressants, increasing the risk of over-sedation.

2. **Antidiabetic Medications:** As documented by Wiciński et al. (2024), Ashwagandha may lower blood glucose levels. When combined with insulin or oral hypoglycemic agents, there is a theoretical risk of hypoglycemia.

3. **Immunosuppressants:** Because of its immunostimulatory properties (Tharakan et al., 2021), it may counteract the effects of medications intended to suppress the immune system, such as those used in organ transplantation or autoimmune disorders.

4. **Thyroid Hormones:** Simultaneous use with levothyroxine may lead to an additive effect, potentially resulting in hyperthyroidism.

6.5. Contraindications and Populations at Risk

Clinicians should exercise caution or avoid the use of *Withania somnifera* in the following populations:

1. **Patients with Hyperthyroidism:** Due to the documented risk of exacerbating thyrotoxicosis (Hayashi et al., 2024).
2. **Autoimmune Diseases:** Potential immunostimulation may theoretically worsen conditions characterized by immune hyperactivity (Tharakan et al., 2021).
3. **Pregnancy and Lactation:** Historically utilized as an abortifacient, and currently lacks sufficient safety data in these populations.
4. **Pre-Surgery Patients:** It is recommended to discontinue use at least two weeks prior to elective surgery due to potential effects on blood sugar levels and potential interactions with anesthetic agents.

7. Systemic Implications of HPA Axis Modulation

Prolonged activation of the HPA axis triggers systemic dysregulation that extends beyond the nervous system, negatively impacting reproductive health, metabolic homeostasis, and immune surveillance. This section synthesizes evidence regarding the secondary physiological benefits of *Withania somnifera* supplementation, which appear to be mediated through both stress reduction and direct tissue-specific mechanisms.

7.1. Impact on the Reproductive System (HPA-HPG Axis Crosstalk)

It is well established that chronic stress acts as a suppressor of the Hypothalamic-Pituitary-Gonadal (HPG) axis, leading to reduced testosterone synthesis and impaired fertility. Nasimi Doost Azgomi et al. (2018) proposed that *Withania somnifera* restores this balance via GABA-mimetic modulation of Gonadotropin-Releasing Hormone (GnRH) and reduction of adrenal interference.

Clinical evidence is particularly robust in male populations with fertility challenges. In a study involving 46 males with oligospermia, Ambiyee et al. (2013) observed that a 90-day supplementation regimen (675 mg daily) yielded a 167% rise in sperm concentration, a 57% gain in motility, and a 53% increase in semen volume. Biochemically, these changes were supported by a 17% increase in serum testosterone and a 34% rise in Luteinizing Hormone (LH). A systematic review by Sengupta et al. (2018) further corroborates these findings, attributing the improvements to the herb's ability to mitigate oxidative stress (ROS) in the seminal plasma and restore the hormonal equilibrium between the HPA and HPG axes.

7.2. Metabolic Regulation: Body Weight and Insulin Sensitivity

Elevated cortisol is a primary driver of visceral adiposity and insulin resistance. In an 8-week trial assessing chronically stressed adults, Choudhary et al. (2017) found that supplementation contributed to a mean weight reduction of 3%, alongside a significant drop in Body Mass Index (BMI). The researchers identified a strong correlation between weight loss and lower scores on the Food Cravings Questionnaire (FCQ), suggesting that the primary mechanism is the mitigation of stress-induced emotional eating behaviors.

Regarding glucose metabolism, Samadi Noshahr et al. (2015) demonstrated in preclinical models that *Withania somnifera* significantly lowers the Homeostasis Model Assessment of Insulin Resistance (HOMA-R) index. This is achieved through the downregulation of pro-inflammatory cytokines such as TNF-alpha and IL-6. While human trials are still emerging, the cumulative data suggest that by stabilizing the HPA axis, *Ashwagandha* acts as a protective agent against metabolic syndrome (Wiciński et al., 2024).

7.3. Physical Performance and Cardiorespiratory Endurance

Since physical exertion acts as a physiological stressor, modulating the stress response can enhance athletic performance. Verma et al. (2024) conducted a randomized controlled trial involving healthy adults and observed a significant improvement in VO₂max following 8 weeks of supplementation.

Furthermore, a Bayesian meta-analysis by Bonilla et al. (2021) identified a robust link between *Ashwagandha* and enhanced muscular recovery kinetics and force production. These ergogenic effects are likely mediated by optimized mitochondrial energy production and a reduction in exercise-induced muscle damage, as evidenced by lower creatine kinase levels in treated subjects (Bonilla et al., 2021). Athletes and healthy adults benefit from improved cardiorespiratory endurance and optimized metabolic recovery, positioning the herb as a valuable ergogenic aid (Choudhary et al., 2015; Sprengel et al., 2025)

7.4. Immunomodulation and Thyroid Function

Glucocorticoids are potent immunosuppressants; therefore, HPA regulation can enhance immune surveillance. Tharakan et al. (2021) demonstrated that *Ashwagandha* exerts an immunostimulatory profile in healthy subjects, characterized by increased expression of immunoglobulins (IgM, IgG) and improved natural killer (NK) cell activity.

The interaction with thyroid function is equally significant. While Gannon et al. (2014) first noted subtle increases in Thyroxine (T4) levels, more definitive evidence was provided by Sharma et al. (2018). In a dedicated trial on patients with subclinical hypothyroidism, 600 mg of root extract daily led to a significant normalization of serum Thyroid-Stimulating Hormone (TSH) and an increase in serum T4 levels. However, the potential for over-stimulation necessitates caution in euthyroid individuals to avoid iatrogenic thyrotoxicosis (Hayashi et al., 2024).

7.5. Influence on Aging and Sleep Parameters

Sleep disturbances are intrinsically linked to HPA axis dysregulation and nighttime cortisol spikes. A systematic review and meta-analysis by Cheah et al. (2021) confirmed that *Withania somnifera* significantly improves sleep efficiency and reduces Sleep Onset Latency (SOL), particularly in individuals with clinical insomnia. These benefits are attributed to the herb's GABAergic activity and its ability to stabilize the circadian rhythm.

In the context of longevity, Vittal and Vinciguerra (2025) have classified Ashwagandha as a potential "geroprotector." Emerging data suggest that its bioactive compounds may modulate telomerase activity and protect against cellular senescence induced by chronic oxidative stress. This positions Ashwagandha not only as a stress-manager but as a tool for extending "healthspan" in aging populations.

8. Impact on Psychosocial Well-being and Sleep Quality

While the biochemical regulation of the HPA axis provides a mechanistic explanation for stress reduction, the clinical value of *Withania somnifera* is ultimately defined by whether it translates into tangible improvements in a patient's daily life. This section examines subjective outcomes -specifically perceived stress, anxiety, and sleep architecture -synthesizing data from randomized controlled trials (RCTs) to distinguish between statistical significance and clinical relevance.

8.1. Mitigation of Perceived Stress and Anxiety Symptoms

Subjective stress is typically quantified using standardized psychometric instruments such as the Perceived Stress Scale (PSS) and the General Health Questionnaire (GHQ-28). In a pivotal study involving adults with a history of chronic stress, Chandrasekhar et al. (2012) demonstrated that 600 mg of root extract daily led to a 44% reduction in PSS scores and a significant improvement across all subscales of the GHQ-28.

These findings are corroborated by Salve et al. (2019), who observed a substantial drop in PSS scores after 8 weeks ($p < 0.001$). What makes this finding particularly compelling is the observed parallel between the psychological relief and the biological downregulation of serum cortisol, suggesting a coherent mind-body response to the supplementation.

However, a more nuanced picture emerges when examining specific anxiety and depression metrics. Lopresti et al. (2019a) utilized the Hamilton Anxiety Rating Scale (HAM-A) alongside the Depression, Anxiety, and Stress Scale (DASS-21). While the intervention successfully reduced anxiety scores ($p = 0.040$), the broader reduction in depressive symptoms was reported as near-significant ($p = 0.096$). This distinction is critical; it suggests that while *Withania somnifera* is a robust anxiolytic agent, its efficacy as a standalone treatment for clinical depression in non-clinical populations requires further investigation. Recent systematic evidence from Marchi et al. (2025) confirms that while effect sizes vary between extracts, the aggregate data consistently favors the intervention over placebo for stress-related anxiety. Comprehensive systematic reviews confirm that Ashwagandha remains one of the most effective herbal alternatives for managing generalized anxiety (Pratte et al., 2014). Emerging digital and online interventions also highlight the plant's role in supporting medical students and professionals facing high-pressure environments (Hassoulas et al., 2025).

8.2. Modulation of Sleep Architecture

Sleep disruption is arguably the most debilitating symptom of chronic HPA axis dysregulation. Cheah et al. (2021) conducted a systematic review and meta-analysis of five RCTs, identifying a statistically significant improvement in sleep quality. The analysis revealed that the benefits are significantly more pronounced in participants diagnosed with clinical insomnia compared to healthy individuals.

The improvements were measurable across three key metrics:

1. **Sleep Onset Latency (SOL):** Significant reduction in the time required to fall asleep.
2. **Total Sleep Time (TST):** Increased overall duration of nighttime rest.
3. **Sleep Efficiency (SE):** Improved ratio of time asleep to time in bed.

Clinical data from Langade et al. (2019, 2021), which utilized both subjective sleep logs and objective actigraphy, confirm these findings. This dual-measurement approach suggests that *Withania somnifera* acts not merely as a general sedative, but as a restorative agent that normalizes GABAergic signaling in hyperaroused states, directly addressing the underlying neurochemistry of insomnia (Mikulska et al., 2023).

8.3. Subjective Well-being and Quality of Life

Beyond specific pathologies, recent literature has focused on the broader concept of quality of life (QoL). As noted in the review by Wiciński et al. (2024), well-being is a multifaceted construct involving physical vitality, emotional stability, and social functioning. For instance, improvements in sexual function and physical performance contribute significantly to overall psychological satisfaction (Chauhan et al., 2022; Bonilla et al., 2021).

Similarly, Choudhary et al. (2017) reported that effective weight management in stressed adults was accompanied by improved scores on the Oxford Happiness Questionnaire. However, it is essential to interpret these "well-being" findings with caution. Subjective quality of life is highly susceptible to the placebo effect, and while the biochemical correlates (such as cortisol reduction) provide a physiological basis, the psychological benefits likely result from a complex interplay between improved sleep quality, metabolic recovery, and the reduction of allostatic load. This holistic improvement in psychological and physical parameters defines the modern role of Ashwagandha in promoting long-term well-being (Wiciński et al., 2025).

9. Discussion

The cumulative evidence from the analyzed literature confirms that *Withania somnifera* acts as a potent multi-target adaptogen capable of stabilizing the HPA axis and mitigating the systemic damage caused by chronic stress. However, several critical factors -ranging from extract standardization to the clinical context of participants -influence the observed outcomes and merit further synthesis.

9.1. Synthesis of Adaptogenic Efficacy and Mechanisms

The core strength of Ashwagandha lies in its pleiotropic nature. While many pharmacological agents target a single receptor or enzyme, the bioactive compounds in Ashwagandha simultaneously modulate neurotransmission, endocrine output, and cellular bioenergetics. As demonstrated in the phytochemical analysis, the GABA-mimetic properties of withanolides (Speers et al., 2021) provide an immediate dampening of cortical hyperarousal. This neurochemical effect is directly linked to the clinical reductions in perceived stress (PSS) and anxiety (HAM-A) scores documented in Chapters 5 and 8. Furthermore, the ability to preserve mitochondrial ATP and optimize the adenylate pool (Bhattacharyya et al., 2009) suggests that Ashwagandha does not merely suppress the stress response but actively enhances physiological resilience.

9.2. Extract Standardization and Dose-Response Variability

A critical observation in this review is the impact of extract standardization on clinical results. The analyzed studies utilized various standardized formulations, most notably KSM-66 and Shoden. While KSM-66 (standardized to 5 percent withanolides) was used in the majority of trials showing significant reductions in serum cortisol (up to 27.9%), higher-potency extracts like Shoden (35% withanolides) demonstrate efficacy at significantly lower dosages. This variability explains why some studies reported only "near-significant" results in certain RCTs -it is likely that different withanolide profiles exert varying degrees of influence on specific neurochemical pathways.

9.3. The Bioavailability and Delivery Systems

As highlighted in the review, withanolides are lipophilic molecules with inherently low aqueous solubility. The clinical success of standardized root extracts in 8-week trials suggests that modern extraction methods successfully overcome these barriers. However, the emerging research into liposomal delivery and the inclusion of sitoindosides (Paul et al., 2021) suggests that the therapeutic index of the plant could be further enhanced, potentially reducing the required dosage while maintaining systemic efficacy.

9.4. Interpreting Systemic Risks: Thyroid and Hepatic Safety

The discussion of safety reveals a "double-edged sword" effect. The thyroid-stimulating property, while therapeutic for subclinical hypothyroidism (Sharma et al., 2018), can become a liability in euthyroid individuals. The case report by Hayashi et al. (2024) serves as a vital reminder that Ashwagandha is a bioactive tool that requires clinical screening for pre-existing thyroid autoimmunity. Similarly, while rare, reports of idiosyncratic liver injury highlight the importance of using high-purity, standardized products to avoid potential adulterants.

9.5. Limitations and Future Perspectives

Despite the high quality of many recent RCTs, several limitations remain. Most trials are limited to 8 or 12 weeks, leaving a gap in knowledge regarding long-term safety. Additionally, there is a lack of data for pediatric and pregnant populations. Future research should prioritize longitudinal studies and head-to-head comparisons of different standardized extracts to establish definitive clinical protocols for stress-related metabolic and reproductive dysfunctions.

10. Conclusions

The comprehensive analysis of contemporary clinical and preclinical literature confirms that *Withania somnifera* (Ashwagandha) is a robust and effective adaptogen, primarily characterized by its ability to modulate the hypothalamic-pituitary-adrenal (HPA) axis. By attenuating the hyperactivation of the stress response, standardized Ashwagandha extracts consistently reduce serum cortisol levels by 11% to 32%, providing a physiological foundation for significant improvements in psychological well-being.

The clinical utility of the herb extends beyond simple anxiolysis. This review has demonstrated that the stabilization of the HPA axis triggers a positive cascade across multiple systemic pathways:

1. **Reproductive Health:** Restoration of the HPG axis, leading to significant improvements in sperm concentration, motility, and testosterone levels in stressed populations.

2. **Metabolic Homeostasis:** Mitigation of stress-induced weight gain and emotional eating, alongside emerging benefits for insulin sensitivity.

3. **Physical Resilience:** Enhanced VO₂max, optimized mitochondrial energy production (ATP), and accelerated muscular recovery.

4. **Sleep Architecture:** Statistically significant improvements in sleep efficiency and sleep onset latency, particularly in individuals with clinical insomnia.

From a safety perspective, *Withania somnifera* remains well-tolerated in the majority of clinical trials. However, its potent stimulatory effect on thyroid hormones and rare idiosyncratic hepatic reactions underscore the importance of clinical monitoring and the use of high-quality, standardized extracts (such as KSM-66 or Shoden).

In conclusion, the integration of *Withania somnifera* into evidence-based protocols for stress management is justified by its multi-systemic regulatory properties. While longitudinal studies are still required to establish long-term safety profiles, the current body of evidence positions Ashwagandha as a vital tool in modern medicine for addressing the complex allostatic load of the 21st century.

Author's Contributions:

Conceptualization: Julia Mieszkowska

Methodology: Julia Mieszkowska, Aleksandra Włodarczyk

Software: Anna Tejchma, Julia Mieszkowska

Check: Norbert Grabias, Julia Mieszkowska

Validation / Check: Paulina Jarzabek, Julia Mieszkowska

Formal Analysis: Maria Rajkowska, Julia Mieszkowska

Investigation: Radosław Gryko, Julia Mieszkowska

Resources: Łukasz Woźniak, Julia Mieszkowska

Data curation: Jędrzej Piotrowski, Julia Mieszkowska

Writing – rough preparation: Aleksandra Włodarczyk, Julia Mieszkowska

Writing – Review and Editing: Julia Mieszkowska, Bernard Myszewski

Supervision / Project Administration: Julia Mieszkowska, Norbert Grabias

All authors have read and agreed to the published version of the manuscript.

Funding Statement: The author received no external funding for this work.

Institutional Review Board Statement: Not applicable; this review included only published data.

Data Availability Statement: All supporting data are available within the cited peer-reviewed literature.

Acknowledgments: The author acknowledges the contribution of investigators and data curators whose high-quality research underpins the advances reviewed herein.

Conflict of Interest Statement: The author declares no conflict of interest.

Declaration of the use of generative AI and AI-assisted technologies in the writing process.

In preparing this work, the authors used ChatGPT for the purpose of improving language and readability. After using this tool, the authors have reviewed and edited the content as needed and accept full responsibility for the substantive content of the publication.

REFERENCES

1. Ambiye, V. R., Langade, D., Dongre, S., et al. (2013). Clinical evaluation of the spermatogenic activity of the root extract of Ashwagandha (*Withania somnifera*) in oligospermic males: A pilot study. *Evidence-Based Complementary and Alternative Medicine*, 2013. <https://doi.org/10.1155/2013/571420>
2. Basta, M., Chrousos, G. P., Vela-Bueno, A., & Vgontzas, A. N. (2007). Chronic insomnia and stress system. *Sleep Medicine Clinics*, 2(2), 279–291. <https://doi.org/10.1016/j.jsmc.2007.04.002>
3. Bhattacharyya, S., Pal, D., Banerjee, D., Majumder, U. K., & Ghosal, S. (2009). Comparative effect of *Withania somnifera* and *Panax ginseng* on swim-stress induced impaired energy status of mice. *Pharmacologyonline*, 2, 421–432. <https://pharmacologyonline.silae.it/files/archives/2009/vol2/041.Sauryya.pdf>
4. Bonilla, D. A., Moreno, Y., Gho, C., Petro, J. L., Odriozola-Martínez, A., & Kreider, R. B. (2021). Effects of Ashwagandha (*Withania somnifera*) on Physical Performance: Systematic Review and Bayesian Meta-Analysis. *Journal of Functional Morphology and Kinesiology*, 6(1), 20. <https://doi.org/10.3390/jfmk6010020>
5. Chandrasekhar, K., Kapoor, J., & Anishetty, S. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. *Indian Journal of Psychological Medicine*, 34(3), 255–262. <https://doi.org/10.4103/0253-7176.106022>
6. Chauhan, S., Srivastava, M. K., & Pathak, A. K. (2022). Effect of standardized root extract of ashwagandha (*Withania somnifera*) on well-being and sexual performance in adult males: A randomized controlled trial. *Health Science Reports*, 5(4), e741. <https://doi.org/10.1002/hsr2.741>
7. Cheah, K. L., Norhayati, M. N., Husniati Yaacob, L., & Abdul Rahman, R. (2021). Effect of ashwagandha (*Withania somnifera*) extract on sleep: A systematic review and meta-analysis. *PLOS ONE*, 16(9), e0257843. <https://doi.org/10.1371/journal.pone.0257843>
8. Choudhary, D., Bhattacharyya, S., & Joshi, K. (2017). Body weight management in adults under chronic stress through treatment with ashwagandha root extract: A double-blind, randomized, placebo-controlled trial. *Journal of Evidence-Based Complementary & Alternative Medicine*, 22(1), 96–106. <https://doi.org/10.1177/2156587216641830>
9. Della Porta, M., Maier, J. A., & Cazzola, R. (2023). Effects of *Withania somnifera* on Cortisol Levels in Stressed Human Subjects: A Systematic Review. *Nutrients*, 15(24), 5015. <https://doi.org/10.3390/nu15245015>
10. Dey, A., Chatterjee, S., & Kumar, V. (2018). Triethylene glycol-like effects of Ashwagandha (*Withania somnifera* (L.) Dunal) root extract devoid of withanolides in stressed mice. *Ayu*, 39(3), 161–166. https://doi.org/10.4103/ayu.AYU_219_16
11. Er, B., Ozmen, B., Sahin, E., Orhan, C., Sahin, N., Morde, A. A., Padigaru, M., & Sahin, K. (2025). A Novel Ashwagandha (*Withania somnifera*) Formulation Mitigates Sleep Deprivation-Induced Cognitive Impairment and Oxidative Stress in a Rat Model. *Biomolecules*, 15(5), 710. <https://doi.org/10.3390/biom15050710>
12. Gannon, J. M., Forrest, P. E., & Roy Chengappa, K. N. (2014). Subtle changes in thyroid indices during a placebo-controlled study of an extract of *Withania somnifera* in persons with bipolar disorder. *Journal of Ayurveda and Integrative Medicine*, 5(4), 241–245. <https://doi.org/10.4103/0975-9476.146566>
13. Gokdemir, G. S., Seker, U., Baksi, N., Baylan, M., Demirtaş, B., & Gokdemir, M. T. (2025). Antidepressant-like effects of ashwagandha (*Withania somnifera*) on chronic unpredictable mild stress-induced depression in adolescent rats. *Psychopharmacology*. <https://doi.org/10.1007/s00213-025-06844-5>
14. Hassoulas, A., McCrum, R., Patel, A., Rashid, K., & Vaidhaya, P. (2025). ACT-based online intervention for obsessive-compulsive traits, anxiety, and depression in medical students: A pilot study [Abstract]. *BJPsych Open*, 11(S1), S39. <https://doi.org/10.1192/bjo.2025.10135>
15. Hayashi, M., Hamada, H., Azuma, S. I., & Hayashi, K. (2024). Painless thyroiditis by *Withania somnifera* (ashwagandha). *Cureus*, 16(3), e55352. <https://doi.org/10.7759/cureus.55352>
16. Herman, J. P., McKlveen, J. M., Ghosal, S., Kopp, B., Wulsin, A., Makinson, R., Scheimann, J. R., & Myers, B. (2016). Regulation of the hypothalamic-pituitary-adrenocortical stress response. *Comprehensive Physiology*, 6(2), 603–621. <https://doi.org/10.1002/cphy.c150015>
17. Jamnekar, P. P., Dehankar, T. J., Bedre, R. V., Dharan, B. G., Agravat, B., & Agravat, H. (2025). Ashwagandha as an adaptogenic herb: A comprehensive review of immunological and neurological effects. *Cureus*, 17(11), e96183. <https://doi.org/10.7759/cureus.96183>
18. Kelgane, S. B., Salve, J., Sampara, P., & Debnath, K. (2020). Efficacy and tolerability of ashwagandha root extract in the elderly for improvement of general well-being and sleep: A prospective, randomized, double-blind, placebo-controlled study. *Cureus*, 12(2), e7083. <https://doi.org/10.7759/cureus.7083>
19. Krishna Raju, A. V., Somepalli, V., Thanawala, S., & Shah, R. (2023). Efficacy and anti-inflammatory activity of ashwagandha sustained-release formulation on depression and anxiety induced by chronic unpredictable stress: In vivo and in vitro studies. *Journal of Experimental Pharmacology*, 15, 291–305. <https://doi.org/10.2147/JEP.S407906>

20. Langade, D., Kanchi, S., Salve, J., Debnath, K., & Ambegaokar, D. (2019). Efficacy and safety of ashwagandha (*Withania somnifera*) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study. *Cureus*, 11(9), e5797. <https://doi.org/10.7759/cureus.5797>
21. Langade, D., et al. (2021). Clinical evaluation of the impact of Ashwagandha on sleep in healthy volunteers and insomnia patients. *Journal of Ethnopharmacology*, 264. <https://doi.org/10.1016/j.jep.2020.113276>
22. Levenson, J. C., Kay, D. B., & Buysse, D. J. (2015). The pathophysiology of insomnia. *Chest*, 147(4), 1179–1192. <https://doi.org/10.1378/chest.14-1617>
23. Lopresti, A. L., et al. (2019a). An investigation into the stress-relieving and pharmacological actions of an Ashwagandha extract. *Medicine*, 98(37). <http://dx.doi.org/10.1097/MD.00000000000017186>
24. Lopresti, A. L., Drummond, P. D., & Smith, S. J. (2019b). A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (*Withania somnifera*) in aging, overweight males. *American Journal of Men's Health*, 13(2). <https://doi.org/10.1177/1557988319835985>
25. Marchi, M., Grenzi, P., Travascio, A., Uberti, D., De Micheli, E., Quartaroli, F., Laquatra, G., Pingani, L., Ferrari, S., & Galeazzi, G. M. (2025). The effect of *Withania somnifera* (Ashwagandha) on mental health symptoms in individuals with mental disorders: Systematic review and meta-analysis. *BJPsych Open*, 11(1), e260. <https://doi.org/10.1192/bjo.2025.10885>
26. Mikulska, P., Malinowska, M., Ignacyk, M., Szustowski, P., Nowak, J., Pesta, K., Szelać, M., Szklanny, D., Judasz, E., Kaczmarek, G., Ejiohuo, O. P., Paczkowska-Walendowska, M., Gościński, A., & Cielecka-Piontek, J. (2023). Ashwagandha (*Withania somnifera*)—Current Research on the Health-Promoting Activities: A Narrative Review. *Pharmaceutics*, 15(4), 1057. <https://doi.org/10.3390/pharmaceutics15041057>
27. Mirjalili, M. H., Moyano, E., Campillo, C., Beltrán, E., & Palazón, J. (2009). *Withania somnifera* (Ashwagandha): A review. *Molecules*, 14(7), 2373–2393. <https://doi.org/10.3390/molecules14072373>
28. Nasimi Doost Azgomi, R., Zomorodi, A., Nazemyieh, H., Fazljou, S. M. B., Bazargani, H. S., Nejatbakhsh, F., Moini Jazani, A., & Ahmadi AsrBadr, Y. (2018). Effects of *Withania somnifera* on reproductive system: A systematic review of the available evidence. *BioMed Research International*, 2018, Article 4076430. <https://doi.org/10.1155/2018/4076430>
29. Pandit, S., Srivastav, A. K., Sur, T. K., Chaudhuri, S., Wang, Y., & Biswas, T. K. (2024). Effects of *Withania somnifera* Extract in Chronically Stressed Adults: A Randomized Controlled Trial. *Nutrients*, 16(9), 1293. <https://doi.org/10.3390/nu16091293>
30. Patriquin, M. A., & Mathew, S. J. (2017). The neurobiological mechanisms of generalized anxiety disorder and chronic stress. *Chronic Stress*, 1. <https://doi.org/10.1177/2470547017703993>
31. Paul, S., Chakrabarti, S., Anand, U., Dey, A., Pandey, D. K., Jha, B. K., Singh, V. K., Huang, Z. S., Xie, T. K., Mukherjee, A., & Proćków, J. (2021). *Withania somnifera* (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, pharmacognosy, and phytochemistry. *Biomedicine & Pharmacotherapy*, 143, Article 112175. <https://doi.org/10.1016/j.biopha.2021.112175>
32. Remenapp, A., Coyle, K., Orange, T., Lynch, T., Hooper, D., Hooper, S., Conway, V., & Hausenblas, H. A. (2022). Efficacy of *Withania somnifera* supplementation on adult's cognition and mood. *Journal of Ayurveda and Integrative Medicine*, 13(2), 100510. <https://doi.org/10.1016/j.jaim.2021.08.003>
33. Salve, J., Pate, S., Debnath, K., & Langade, D. (2019). Adaptogenic and anxiolytic effects of Ashwagandha root extract in healthy adults: A double-blind, randomized, placebo-controlled clinical study. *Cureus*, 11(12), e6466. <https://doi.org/10.7759/cureus.6466>
34. Samadi Noshahr, Z., Shahraki, M. R., Ahmadvand, H., Nourabadi, D., & Nakhaei, A. (2015). Protective effects of *Withania somnifera* root on inflammatory markers and insulin resistance in fructose-fed rats. *Reports of Biochemistry & Molecular Biology*, 3(2), 62–67. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757043/>
35. Sengupta, P., Agarwal, A., Pogrebetskaya, M., Roychoudhury, S., Durairajanayagam, D., & Henkel, R. (2018). Role of *Withania somnifera* (ashwagandha) in the management of male infertility. *Reproductive BioMedicine Online*, 36(3), 311–326. <https://doi.org/10.1016/j.rbmo.2017.11.007>
36. Sharma, A. K., Basu, I., & Singh, S. (2018). Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients. *Journal of Alternative and Complementary Medicine*, 24(3). <https://doi.org/10.1089/acm.2017.0183>
37. Shukla, K. K., Mahdi, A. A., Mishra, V., Rajender, S., Sankhwar, S. N., Patel, D., & Das, M. (2011). *Withania somnifera* improves semen quality by combating oxidative stress and cell death and improving essential metal concentrations. *Reproductive BioMedicine Online*, 22(5), 421–427. <https://doi.org/10.1016/j.rbmo.2011.01.010>
38. Singh, N., Bhalla, M., de Jager, P., & Gilca, M. (2011). An overview on ashwagandha: A Rasayana of Ayurveda. *African Journal of Traditional, Complementary and Alternative Medicines*, 8(5S), 208–213. <https://doi.org/10.4314/ajtcam.v8i5S.9>
39. Sinha, R. (2008). Chronic stress, drug use, and vulnerability to addiction. *Annals of the New York Academy of Sciences*, 1141(1), 105–130. <https://doi.org/10.1196/annals.1441.030>

40. Speers, A. B., Cabey, K. A., Soumyanath, A., & Wright, K. M. (2021). Effects of *Withania somnifera* on GABAergic signaling: Evidence for prophylactic and therapeutic use in psychiatric and neurological disorders. *Current Neuropharmacology*, 19(9), 1461–1485. <https://doi.org/10.2174/1570159X19666210712151556>
41. Sprengel, M., Laskowski, R., & Jost, Z. (2025). *Withania somnifera* (ashwagandha) supplementation: A review of its mechanisms, health benefits, and role in sports performance. *Nutrition & Metabolism*, 22, 9. <https://doi.org/10.1186/s12986-025-00902-7>
42. Tharakan, A., Shukla, H., Benny, I. R., Tharakan, M., George, L., & Koshy, S. (2021). Immunomodulatory effect of *Withania somnifera* (ashwagandha) extract—A randomized, double-blind, placebo controlled trial with an open label extension on healthy participants. *Journal of Clinical Medicine*, 10(16), 3644. <https://doi.org/10.3390/jcm10163644>
43. Verma, N., Gupta, S. K., Patil, S., Tiwari, S., & Mishra, A. K. (2024). Effects of ashwagandha (*Withania somnifera*) standardized root extract on physical endurance and VO₂max in healthy adults performing resistance training: An eight-week, prospective, randomized, double-blind, placebo-controlled study [version 2; peer review: 1 approved, 2 approved with reservations]. *F1000Research*, 12, 335. <https://doi.org/10.12688/f1000research.130932.2>
44. Vittal, M., & Vinciguerra, M. (2025). Enhancing healthspan with ashwagandha (*Withania somnifera*): A comprehensive review of its multifaceted geroprotective benefits. *Biogerontology*, 26, 179. <https://doi.org/10.1007/s10522-025-10320-0>
45. Wiciński, M., Fajkiel-Madajczyk, A., Kurant, Z., Liss, S., Szyperski, P., Szambelan, M., Gromadzki, B., Rupniak, I., Słupski, M., & Sadowska-Krawczyńska, I. (2024). Ashwagandha's Multifaceted Effects on Human Health: Impact on Vascular Endothelium, Inflammation, Lipid Metabolism, and Cardiovascular Outcomes—A Review. *Nutrients*, 16(15), 2481. <https://doi.org/10.3390/nu16152481>
46. Wiciński, M., Fajkiel-Madajczyk, A., Sławatycki, J., Szambelan, M., Szyperski, P., Wojciechowski, P., Wójcicki, J., & Gawryjolek, M. (2025). Ashwagandha (*Withania somnifera*) and Its Effects on Well-Being—A Review. *Nutrients*, 17(13), 2143. <https://doi.org/10.3390/nu17132143>
47. Yang, L., Zhao, Y., Wang, Y., Liu, L., Zhang, X., Li, B., & Cui, R. (2015). The effects of psychological stress on depression. *Current Neuropharmacology*, 13(4), 494–504. <https://doi.org/10.2174/1570159X1304150831150507>
48. Yaribeygi, H., Panahi, Y., Sahraei, H., Johnston, T. P., & Sahebkar, A. (2017). The impact of stress on body function: A review. *EXCLI Journal*, 16, 1057–1072. <https://doi.org/10.17179/excli2017-480>